Physician profile
Neda Karimi
NPI 1023161676
$760.60
in general payments reported to CMS, 2019-2025
13 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.49 · 2020: $134 · 2021: $77.15 · 2022: $52.19 · 2024: $213 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $172.28 | 2025 | Hydrus Microstent, Voyager Dslt |
| Amgen INC. | $130.25 | 2024 | Uplizna |
| Optos, INC. | $117.12 | 2020 | |
| Dompe US, INC. | $68.24 | 2021-2024 | Oxervate |
| Abbvie INC. | $52.19 | 2022 | |
| Sun Pharmaceutical Industries INC. | $49.93 | 2025 | |
| Mallinckrodt Hospital Products INC. | $44.92 | 2021 | |
| Biotissue Holdings INC. | $24.57 | 2024 | |
| Oyster Point Pharma, INC. | $22.62 | 2025 | Tyrvaya |
| Rxsight INC | $22.59 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $20.49 | 2019 | |
| Bausch & Lomb Americas INC. | $18.16 | 2025 | Miebo |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neda Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.